Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While LL-37 works as a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
LL-37
CAMP
Semaglutide
GCG
LL-37 and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: LL-37 is more often discussed in the realm of Immunology and inflammation and Gastroenterology, whereas Semaglutide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with LL-37 tracking more closely to GPCR receptor while Semaglutide centers more on GLP-1 receptor. LL-37 has a more natural endogenous origin, while Semaglutide is closer to synthetic analog background and their development context also differs, with LL-37 in Preclinical development while Semaglutide is approved. LL-37 takes the form of a linear peptide, whereas Semaglutide is closer to a peptide conjugate, while Semaglutide incorporates lipidation features that are not part of LL-37.